1. Clinical & Scientific Overview
Salicylic Acid (Cosmetic BHA 0.5%–2.0%) (TIP-MED-000609, Reference Code [COS-05]) is classified under
Cosmetics & Cosmeceutical Ingredients (Cosmetics Rules, 2020) as a Cosmetic Science & Dermopharmaceutics • Lipophilic Keratolytic, Comedolytic & Anti-Dandruff Beta-Hydroxy Acid.
Within the Indian regulatory and compendial framework, it is governed under Regulated under IS 4707 (Part 2) / Cosmetics Rules, 2020 up to 2.0% in leave-on skin care and 3.0% in rinse-off hair care; higher strengths (6%–40% wart/callus/psoriasis ointments) are drug formulations..
INCI Standard: Salicylic Acid (IS 4707 / Cosmetics Rules, 2020 Compliant)
Leave-on facial products: 0.5% to 2.0% max; Rinse-off hair shampoos: up to 3.0%; pH 3.0–4.2
Dermopharmaceutics, INCI Formulation & Cosmetics Rules 2020 Compliance
Salicylic AcidLipophilic Keratolytic, Comedolytic & Anti-Dandruff Beta-Hydroxy Acid
Leave-on facial products: 0.5% to 2.0% max; Rinse-off hair shampoos: up to 3.0%; pH 3.0–4.2
Irritation, Sensitisation & Photoprotection Considerations: Over-exfoliation causes barrier stripping, xerosis, and contact irritation; strictly prohibited in cosmetic preparations for children under 3 years of age (except shampoos) due to percutaneous salicylate absorption risk.
Chemical Stability & Formulation Incompatibilities: Incompatible with iron salts (forms purple ferric salicylate complex); precipitates below pH 2.5 in purely aqueous vehicles without cosolvents (propylene glycol, betaine, or cyclodextrin).
Statutory Cosmetic vs Drug Distinction (Cosmetics Rules, 2020 & BIS IS 4707): Regulated under IS 4707 (Part 2) / Cosmetics Rules, 2020 up to 2.0% in leave-on skin care and 3.0% in rinse-off hair care; higher strengths (6%–40% wart/callus/psoriasis ointments) are drug formulations.
3. Mechanism of Action & Pharmacodynamics
Ortho-hydroxybenzoic acid whose aromatic benzene ring confers lipophilicity, allowing it to partition into sebum-filled pilosebaceous follicles and dissolve intercellular corneodesmosomes (desmolytic action) to shed hyperkeratotic corneocytes.
4. Therapeutic Indications & Evidence-Supported Uses
- Cosmetic exfoliation of oily, comedone-prone skin (0.5–2.0%)
- Rinse-off scalp exfoliation in dandruff shampoos
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Cosmetic Formulation Concentration & pH Window: Leave-on facial products: 0.5% to 2.0% max; Rinse-off hair shampoos: up to 3.0%; pH 3.0–4.2
Administration & Meal Timing: External topical use only (Leave-on facial products: 0.5% to 2.0% max; Rinse-off hair shampoos: up to 3.0%; pH 3.0–4.2). Incompatible with iron salts (forms purple ferric salicylate complex); precipitates below pH 2.5 in purely aqueous vehicles without cosolvents (propylene glycol, betaine, or cyclodextrin).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Stratum corneum partitioning and epidermal retention governed by molecular weight (<500 Da rule), logP, and formulation pH; cosmetic ingredients are formulated for local epidermal/corneocyte conditioning without systemic pharmacological action.
Local epidermal enzymatic hydrolysis or oxidation where applicable (e.g., esterases for retinyl/tocopheryl esters).
Not applicable (topical cosmetic ingredient with negligible systemic exposure when used on intact skin).
Not applicable (topical external cosmetic use).
7. Contraindications, Precautions & High-Risk Warnings
- Known allergic contact dermatitis or hypersensitivity to Salicylic Acid
- Application to open wounds, abraded skin, or acute infectious dermatoses
- Over-exfoliation causes barrier stripping, xerosis, and contact irritation; strictly prohibited in cosmetic preparations for children under 3 years of age (except shampoos) due to percutaneous salicylate absorption risk.
Key Clinical Precautions: Over-exfoliation causes barrier stripping, xerosis, and contact irritation; strictly prohibited in cosmetic preparations for children under 3 years of age (except shampoos) due to percutaneous salicylate absorption risk.
8. Adverse Effects Profile
- Over-exfoliation causes barrier stripping, xerosis, and contact irritation; strictly prohibited in cosmetic preparations for children under 3 years of age (except shampoos) due to percutaneous salicylate absorption risk.
- Over-exfoliation causes barrier stripping, xerosis, and contact irritation; strictly prohibited in cosmetic preparations for children under 3 years of age (except shampoos) due to percutaneous salicylate absorption risk.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Incompatible with iron salts (forms purple ferric salicylate complex); precipitates below pH 2.5 in purely aqueous vehicles without cosolvents (propylene glycol, betaine, or cyclodextrin).
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Formulation Stability & Compatibility Check: Incompatible with iron salts (forms purple ferric salicylate complex); precipitates below pH 2.5 in purely aqueous vehicles without cosolvents (propylene glycol, betaine, or cyclodextrin).
Pharmacist Patient Counselling Points:
- Perform a 24–48 hour forearm patch test before introducing a new active cosmeceutical onto facial skin.
- Apply broad-spectrum SPF 30+ PA+++ sunscreen every morning, especially when using AHAs, BHAs, retinol, or brightening actives.
- Cosmetic products clean, condition, or protect superficial skin appearance; persistent acne, melasma, rosacea, or eczema requires medical dermatology evaluation.
Storage, Stability & Dispensing Safeguards: Incompatible with iron salts (forms purple ferric salicylate complex); precipitates below pH 2.5 in purely aqueous vehicles without cosolvents (propylene glycol, betaine, or cyclodextrin).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Cosmetics Rules, 2020 (CDSCO, Ministry of Health & Family Welfare, Govt. of India); Bureau of Indian Standards (BIS) IS 4707 (Part 1 & Part 2) Classification of Cosmetic Raw Materials and Adjuncts.
Official Verification Portals: CDSCO — Cosmetics Division & Cosmetics Rules, 2020 • Bureau of Indian Standards (BIS) — IS 4707 Cosmetic Standards
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.